Citadel Advisors
ACRV icon

Citadel Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Citadel Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.5K Buy
+41,276
New +$70.1K ﹤0.01% 12895
2026
Q1 		– Sell
-1,641,884
Closed -$3.96M – 12868
2025
Q4 		$3.96M Buy
1,641,884
+100,558
+7% +$219K ﹤0.01% 4675
2025
Q3 		$2.79M Sell
1,541,326
-354,193
-19% -$498K ﹤0.01% 5434
2025
Q2 		$2.26M Hold
1,895,519
– – ﹤0.01% 5481
2025
Q1 		$3.85M Sell
1,895,519
-224,127
-11% -$1.21M ﹤0.01% 4320
2024
Q4 		$12.8M Sell
2,119,646
-20,982
-1% -$152K ﹤0.01% 2662
2024
Q3 		$15M Buy
2,140,628
+20,982
+1% +$165K ﹤0.01% 2380
2024
Q2 		$12.3M Buy
2,119,646
+439,619
+26% +$3.54M ﹤0.01% 2519
2024
Q1 		$12M Buy
1,680,027
+30,368
+2% +$141K ﹤0.01% 2691
2023
Q4 		$8.12M Sell
1,649,659
-798
-0% -$4.21K ﹤0.01% 3122
2023
Q3 		$15.8M Buy
1,650,457
+811
+0% +$9.37K ﹤0.01% 2135
2023
Q2 		$21.4M Buy
1,649,646
+8,624
+0.5% +$104K ﹤0.01% 1816
2023
Q1 		$20.1M Buy
1,641,022
+6,918
+0.4% +$116K ﹤0.01% 1906
2022
Q4 		$18.2M Buy
+1,634,104
New +$20.7M ﹤0.01% 2065

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's ACRV Position: Q2 2026 in Review

Citadel Advisors opened a new position in Acrivon Therapeutics (ACRV) in Q2 2026: 41,276 shares worth $73.5K. The stake represents ﹤0.01% of the portfolio and ranks #12895 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ACRV as recently as Q4 2025.

Citadel Advisors first reported a position in ACRV in Q4 2022 and has held it in 14 quarters since. The position peaked at $21.4M in Q2 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Citadel Advisors held 41,276 shares of Acrivon Therapeutics worth $73.5K as of Q2 2026.
  • Acrivon Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Acrivon Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12895 holding.
  • Citadel Advisors first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Citadel Advisors's Acrivon Therapeutics position peaked at $21.4M in Q2 2023.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.